In addition, using pharmacological inhibition and genetic depletion approaches, we formally identified ADAM10 and ADAM17 as the targeted proteases, thereby establishing WNF as a potent α-secretase enhancer and a possible anti-AD agent. Here, ADAM10 is linked to Alzheimer disease.